16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

Inclusion Criteria: * Male or non-pregnant, non-lactating female patients * Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray) fulfilling the Modified New York criteria for AS (1984) * Patients should have been on NSAIDs with an inadequate response * Patients who were regularly taking NSAIDs as part of their AS therapy are required to be on a stable dose * Patients who had been on an anti-TNFα agent (not more than one) must have experienced an inadequate response Exclusion Criteria: * Chest X-ray (or MRI) with evidence of ongoing infectious or malignant process * Patients with total ankylosis of the spine * Patients previously treated with any biological immunomodulating agents except for those targeting TNFα * Previous treatment with any cell-depleting therapies